Judge: FDA can't police drugs alone

As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, the judge said lawsuits play a vital role in drug safety. Without them, claims of safety problems "might well go unaddressed," Judge Mark Rindner told the court. Evidence the State of Alaska presented over the past two weeks, he said, shows that the FDA "isn't capable of policing this matter."

Why the commentary? After the state rested its case, Lilly asked the judge for an immediate verdict in its favor (a routine step at this stage of a trial). The FDA should be dealing with these matters, not states, the lawyer said. Rindner, of course, begged to differ.

So the case proceeded. Lilly trotted out a couple of experts: One not only questioned the link between Zyprexa and diabetes, but the link between weight gain and diabetes. Another said doctors should have known about the weight gain problems anyway, and that Zyprexa's side effects are far outweighed by its benefits. The drugmaker will continue to tell its side of the Zyprexa story this week. Stay tuned.

- read the story at the Anchorage Daily News
- check out the item at Pharmalot

Related Articles:
Did Lilly chief support off-label promos? Report
Former FDAer: Lilly hid risks for profit. Report
Lilly gears up for Alaska's Zyprexa trial. Report
Lilly strengthens Zyprexa warnings. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.